Haemonetics' first quarter revenue grew 5.6% to $339.4M, prompting a raise in FY2027 guidance.

Haemonetics reported first quarter fiscal 2027 revenue of $339.4 million, an increase of 5.6% year-over-year, and adjusted earnings per share of $1.14, up 3.6%. The results surpassed analyst expectations, driven by growth across its business segments.

Key Highlights

• Organic revenue increased 5.9%, led by 8.2% organic growth in the Plasma business and 5.9% in MedSurg.
• The company raised its full-year fiscal 2027 guidance for organic revenue growth to a range of 4-7%, up from the previous 3-6%.
• Interventional Technologies returned to growth with a 2.8% organic increase year-over-year.